The 25 Biggest Insider Purchases in October

Page 21 of 25

5. Allogene Therapeutics Inc (NASDAQ:ALLO)

Who Bought Shares: President and CEO David D. Chang

How Many Shares Were Bought: 40,000 @ $18.00 per share

Date of the Transaction(s): October 15

Allogene Therapeutics Inc (NASDAQ:ALLO)’s CEO was one of several insiders to buy shares during the company’s IPO in the middle of October. Those shares have been on fire over the past week, gaining more than 20%. Allogene currently has one treatment in phase 1 testing, that being its lead investigational product UCART19. It also has 16 other CAR T treatments in pre-clinical testing.

Follow Allogene Therapeutics Inc. (NASDAQ:ALLO)

Page 21 of 25